Biotech Stocks Facing FDA Decision In July 2021

2 / 14

The FDA decision on Pfizer Inc.’s (PFE) Abrocitinib, proposed for the treatment of adults and adolescents with moderate to severe atopic dermatitis, is expected early in the third quarter.

Abrocitinib is an oral small molecule that selectively inhibits Janus kinase (JAK) 1. Inhibition of JAK1 is thought to modulate multiple cytokines involved in pathophysiology of atopic dermatitis.

Topical steroids are the mainstay treatment for mild-to-moderate atopic dermatitis. Oral corticosteroids like Prednisone and Sanofi/Regeneron’s Dupixent are the other treatment options for atopic dermatitis.

If approved, Abrocitinib is expected to achieve peak sales of $1.5 billion by 2027, according to GlobalData.

PFE closed Wednesday’s (Jun.23, 2021) trading at $39.05, down 1.41%.